IP Library Granted Patent US 7,964,212
Granted Patent B2
US 7,964,212 · App. 12/367,928 · Granted Jun 21, 2011

Effervescent compositions comprising phosphonates and methods related thereto

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,964,212
App. No.
12/367,928
Granted
Jun 21, 2011
Kind
B2
Abstract

The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.

Claims (9)

1. An effervescent composition comprising:

(a) 50 mg to 120 mg of a bisphosphonate

(b) citric acid, and

(c) an alkaline effervescing component which is a carbonate salt or a bicarbonate salt, wherein the composition has a total weight of 3500 mg to about 6000 mg and when dissolved in water produces a solution having a buffered pH of about 4 to about 6.5 and has buffering capacity sufficient to mediate the pH of a patient's stomach for at least 15 minutes.

2. The composition of claim 1 , wherein the bisphosphonate is selected from the group consisting of etidronate, risedronate, ibandronate, alendronate, and combinations thereof.

3. The composition of claim 1 , wherein the bisphosphonate is alendronate and said buffering capacity sufficient to mediate the pH of a patient's stomach for at least 30 minutes.

4. The composition of claim 1 , wherein the dissolved buffered solution is capable of mediating the pH of a patient's stomach for at least about 30 minutes or more.

5. The composition of claim 1 , wherein the alkaline effervescing component comprises a carbonate salt and a bicarbonate salt.

6. The composition of claim 1 , wherein the acid component and the alkaline effervescing component are at least partially reacted with each other during granulation with the bisphosphonate.

Assignments (6)
CHANGE ASSIGNEE'S ADDRESS Recorded Sep 17, 2013
From: EFFRX PHARMACEUTICALS SA
To: EFFRX PHARMACEUTICALS SA
Reel/Frame 031227/0035 →
LIEN Recorded Jul 11, 2012
From: EFFRX INC
To: ATENEUM AB, REG. NO. 556521-4391
Reel/Frame 028531/0063 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 24, 2011
From: EFFRX, INC.
To: EFFRX PHARMACEUTICALS SA
Reel/Frame 027111/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2010
From: MCCALLISTER, DAVID; ROSEN, CHRISTER
To: LIFIZZ, INC.
Reel/Frame 024197/0121 →
CHANGE OF NAME Recorded Apr 7, 2010
From: LIFIZZ, INC.
To: EFFRX, INC.
Reel/Frame 024197/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2009
From: ROSEN, CHRISTER
To: EFFRX, INC.
Reel/Frame 022647/0500 →
Continuity (3)
Continuation 10273081 · Oct 17, 2002
Continuation In Part 10092083 · Mar 6, 2002
Related Publication 20090142278A1 · Jun 4, 2009